Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
2002 1
2005 1
2006 2
2007 1
2008 2
2009 3
2010 2
2011 4
2012 5
2013 2
2014 2
2015 1
2016 3
2017 6
2018 5
2019 4
2020 1
2021 4
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
Chen CD, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay NS, Hobbs DA, Hornbeck R, Fagan AM, Cruchaga C, Goate AM, Perrin RJ, Wang G, Li Y, Shi X, Xiong C, Pontecorvo MJ, Klein G, Su Y, Klunk WE, Jack C, Koeppe R, Snider BJ, Berman SB, Roberson ED, Brosch J, Surti G, Jiménez-Velázquez IZ, Galasko D, Honig LS, Brooks WS, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters CL, van Dyck CH, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford DB, Mills S, Supnet-Bell C, McDade E, Bateman RJ, Benzinger TLS; DIAN-TU Study Team. Chen CD, et al. Among authors: mills s. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 37017737 Free PMC article. Clinical Trial.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Libre-Guerra JJ, McCullough A, Joseph-Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: mills sl. Alzheimers Dement (Amst). 2022 Nov 3;14(1):e12367. doi: 10.1002/dad2.12367. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36348972 Free PMC article.
Longitudinal analysis of symptoms in the Ehlers-Danlos syndromes.
Schubart JR, Mills SE, Schaefer EW, Bascom R, Francomano CA. Schubart JR, et al. Among authors: mills se. Am J Med Genet A. 2022 Apr;188(4):1204-1213. doi: 10.1002/ajmg.a.62640. Epub 2022 Jan 7. Am J Med Genet A. 2022. PMID: 34994522 Free PMC article.
53 results